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Introduction: Pseudomonas aeruginosa is a corneal pathogen and may cause corneal ulceration.  
The goal of this study was to determine the potential of PCR for detecting P. aeruginosa in 
corneal specimens from patients with keratitis.  
Study Aims: 1) To establish a specific real-time PCR assay to detect P. aeruginosa.  2) To 
determine a secondary target for P. aeruginosa that may provide a universal target for other 
bacterial pathogens.  3) To validate both assays for diagnostic testing with true positive and true 
negative clinical samples. 
Methods: 1) Analytical studies were conducted by testing P. aeruginosa and other bacteria 
isolated from patients with keratitis with a PCR assay designed to amplify the ecfX gene of P. 
aeruginosa.  The outcome parameters were limit of detection, and amplification efficiency.  2) 
Similarly, P. aeruginosa isolates were tested for the 16S rRNA gene using the same parameters.  
3) Validation of both assays was done by testing 20 cornea samples known to be positive for P. 
aeruginosa and 20 clinical samples known to be negative for P. aeruginosa DNA. Descriptive 
statistics were determined. PAGE analysis was performed to confirm the presence of amplified 
product. 
Results: 1) Amplification efficiency of the ecfX assay was 96.6%, with a limit of detection of 
33.6 copies of target DNA/µl.  All 21 P. aeruginosa isolates were detected, with no detection of 
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the 35 non-P. aeruginosa isolates.  2) Amplification efficiency of the 16S rRNA assay was 
103.4%, with a limit of detection of 8.12 copies /µl.  All 21 P. aeruginosa isolates were detected.  
3) The sensitivity, specificity, positive predictive value, negative predictive value, and efficiency 
for the ecfX and 16S rRNA assays were, [75%, 95%, 94%, 79%, and 85%], and [70%, 100%, 
100%, 77%, and 85%], respectively.  PAGE analysis supported specificity of the DNA amplified 
products.  
Conclusions: Both real-time PCR assays used in this study detected P. aeruginosa DNA from 
keratitis patient samples.  These results indicate that aside from culture, PCR may be a useful 
adjunct method in the diagnosis of keratitis patients.   
Public H ealth R elevance: Real-time PCR can be used to detect P. aeruginosa from patients 
with keratitis to help preserve vision. 
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1.0  INTRODUCTION 
1.1 PSEUDOMONAS AERUGINOSA HISTORY 
Since the mid-1800s, researchers and physicians have been observing and studying P. 
aeruginosa-related infections.  P. aeruginosa was most likely first identified by Luke in 1862, 
when he found rod-shaped particles in pus-filled infections (25).  Twelve years earlier, in 1850, 
Sédillot had made similar observations on surgical wound dressings (24).  Gessard was the first 
person to actually isolate and culture this bacterium from infections, naming it Bacillus 
pyocyaneus in “On the Blue and Green Coloration of Bandages” (24, 25).  In 1916, Freeman 
gave a more detailed description about the infection process of P.  aeruginosa (24).     
1.2 PSEUDOMONAS AERUGINOSA BIOLOGY 
The bacterial species, P. aeruginosa, is a member of the Gamma Proteobacteria class of bacteria 
and falls under the bacterial family of Pseudomonadaceae (38).  P. aeruginosa is a Gram-
negative, oxidase-positive, non-fermenting, rod-shaped bacterium that lives freely in soil or 
water environments (38).  P. aeruginosa is found in the form of a biofilm or as a single 
microorganism with a single flagellum in the environment.  In culture, clinical samples normally 
have either a smooth or mucoid appearance growing on a blood agar plate.  It grows optimally at 
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37°C, but it can grow at temperatures up to 42°C (38).  This bacterium’s ability to survive with a 
limited nutritional supply and ability to adapt to different physical conditions allow it to thrive in 
hospital and community environments (24).  P. aeruginosa possesses two types of soluble 
pigments, which include a fluorescent pigment, pyoverdin and a blue pigment, pyocyanin (38).  
Pyoverdin gives this pathogen a fluorescent characteristic, allowing it to be identified under 
ultraviolet light, while pyocyanin is vital to iron metabolism (38). 
Aside from being able to grow at these high temperatures, this pathogen is resistant to 
high concentrations of certain antibiotics, as well as salts/dyes and weak antiseptics.  The high 
level of resistance to these antibiotics is due to the organism’s structure, specifically the Gram-
negative outer membrane.  Some strains possess plasmids with antibiotic resistance genes that 
can be horizontally transferred to other bacteria, increasing the problem of multi-resistant P. 
aeruginosa.  By nature, P. aeruginosa is an opportunistic pathogen, which means that it will 
infect an anatomical site only when the immune system has been weakened or the site has been 
compromised in some way or when it gains access to tissue or the bloodstream (38). For 
example, if the cornea becomes irritated from contact lens wear, this provides an opportunity for 
P. aeruginosa to infect that area. 
1.3 PSEUDOMONAS AERUGINOSA PATHOGENESIS 
The main infections that this pathogen causes include the following: urinary tract infections, 
bacteremia, bone and joint infections, gastrointestinal infections, and systemic infections.  People 
at a high risk of infection are patients dealing with life-threatening burns, cancer, cystic fibrosis, 
or AIDS because their immune systems are not very strong at combating pathogens (38).  In 
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addition to these types of cases, P. aeruginosa may cause keratitis, which can eventually result in 
corneal scarring and vision impairment (5).  A break in the epithelial barrier provides P. 
aeruginosa with an opportunity to cause infection by way of its type 4 pili and flagellum (7).  
This pathogen possesses several virulence factors which play a role in the infection process.  
Exotoxin A blocks the protein biosynthesis and causes cell death by catalyzing ADP-ribosylation 
and inactivating elongation factor 2 (41).  Exoenzyme S also catalyzes ADP-ribosylation like 
exotoxin A but instead, targets GTP-binding proteins (12).  This action then leads to the 
breakdown of tissue in the lungs (29), which causes problems for patients suffering from cystic 
fibrosis.  Two virulence factors that work together are phospholipase C and rhamnolipids.  
Rhamnolipids increase the solubility of the phospholipids of lung surfactant, which allows for 
phospholipase C to more effectively cause damage to the lungs (7).  Alkaline protease has been 
studied and found to cause damage to the corneal surface of the eye, in addition to potentially 
acting as a colonization factor (11).  In addition to these virulence factors, elastase B, protease 
IV, and P. aeruginosa small protease play an integral part to the infection process of P. 
aeruginosa (5).  Figure 1 mentions several virulence factors involved in the infection process.  
Two different phenotypes of P. aeruginosa from corneal isolates exist—cytotoxic and invasive 
strains.  The cytotoxic strains have been reported to cause corneal edema, while the invasive 
strains have led to corneal ulceration (22).   
1.4 MICROBIAL KERATITIS 
Infectious keratitis, a medical condition which can be caused by bacterial, fungal, amoeboid, or 
viral pathogens, refers to inflammation of the cornea, leading to damage of the epithelial tissue 
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of the cornea (15).  If this condition is left untreated, patients can suffer long-term damage to 
their cornea or rarely lose their vision in only 24 hours (19); therefore, quick and effective 
treatment is crucial for preservation of a patient’s eyesight.  Symptoms associated with keratitis 
include redness in the eye, tenderness in the eye, altered vision, sensitivity to light, and tearing 
(28).  Each year, it is estimated that about 500,000 people fall victim to ulcerative keratitis in the 
world, with about 30,000 of these cases occurring in the United States (42).   
A leading risk factor of microbial keratitis involves people who wear contact lenses, with 
this group at a 10-fold higher risk than the rest of the population (28).  Contact lens wear 
associated P. aeruginosa infections affects about 10 to 30 people per 100,000 people per year in 
the United States (19).  Gram-negative isolates are related to 10-50% of bacterial keratitis cases 
in the United States (19).  Patients suffering from Gram-negative infections will experience pus 
and mucus surrounding the eye, indicative of necrotic destruction of the corneal epithelium (10).  
P. aeruginosa is the leading Gram-negative isolate linked to bacterial keratitis cases (19). 
  
 
Figure 1. P. aeruginosa virulence factors and corneal host response to keratitis infection (43). 
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1.5 HOST RESPONSE TO KERATITIS 
In a healthy individual, tears and blinking of the eyes protect people’s eyes from bacterial 
infection, in addition to mucus on the tear layer (25).  For those cases where opportunistic 
pathogens gain entry to the eye, the host reacts with an inflammatory response, which causes 
substantial damage while trying to combat the foreign pathogen (Figure 1).  Toll-like receptors 
recognize pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide which is 
found in Gram-negative bacteria, and inform the host to engage in phagocytosis or to activate 
pro-inflammatory pathways (1).  Exoproducts released from host corneal cells and activated 
leukocytes cause the destruction of the corneal epithelial tissue (10).  Polymorphonuclear 
leukocytes (PMN) have been studied extensively and have been shown to serve as a protective 
agent of the immune system in combating ocular infections.  One study showed that when PMNs 
were selectively deleted from mice or when its expression was blocked and the mice were then 
exposed to P. aeruginosa in the eye, the mice died significantly quicker than mice with a normal 
functioning innate immune system (10).  On the other hand, studies have shown that even though 
PMN helps in combating an ocular P. aeruginosa attack, they also cause damage to the ocular 
area through cytokine activity and their time of activation (10).   
1.6 KERATITIS DIAGNOSIS AND TREATMENT 
Accurate and quick diagnosis of keratitis is the first step to obtaining the proper treatment for this 
medical condition.  Diagnostic tests targeting corneal pathogens are expected to have high 
sensitivity and specificity values, as well as simple sample collection methods, quick transport of 
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the specimen to a laboratory, and results in 24 to 72 hours (20).  Physicians must make sure to 
obtain two corneal specimens from the infected patient’s eye, in order for the clinical 
laboratories to examine one specimen for the presence of microorganisms and use the other 
specimen for staining, such as the Gram stain (20).  In addition to antibiotic susceptibility testing, 
the laboratories will culture the isolated specimens and observe growth for at least a five day 
period (20).  Clinical ophthalmic laboratories normally are able to positively identify a causative 
pathogen through culture in 40% to 60% of cases (17).   
If physicians suspect keratitis, there are a few different tests they can perform to identify 
the causative agent after obtaining a past medical history from the patient.  A typical eye exam 
can be performed on patients to test their vision, in addition to a visual acuity test to observe how 
well patients’ eyes are capable at handling seeing from different distances (30).  A slit-lamp test 
allows for the physician to observe the ocular surface, as well as the inner structures of the eye, 
with the use of a microscope (30).  This type of test also utilizes fluorescein dye eyedrops, in 
order to more easily detect a defect on the corneal surface (40).  The staining pattern of this dye 
on a patient’s eye can help physicians determine the cause of the problem (28).  Biopsies, and 
blood tests are two other types of tests that physicians can order to confirm a keratitis diagnosis 
(30).  With the biopsy, a small piece of corneal tissue can be isolated from a patient with keratitis 
and then the cells can be viewed under a microscope, in order to identify any abnormalities. 
Blood tests can provide physicians with a better understanding of the immune system response to 
the corneal infection (30).   
In terms of providing patients with proper treatment, antibiotic resistance has been an 
increasing problem for researchers and physicians over the past few decades.  Bacteria, such as 
P. aeruginosa, have the ability to become resistant to antibiotics through the transfer of resistant 
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genes encoded in plasmids from one bacterium to another or through information encoded in 
chromosomes (24).  Although antibiotic resistance is a growing concern, physicians usually treat 
patients who are suffering from a corneal infection with fluoroquinolones (5).  Ciprofloxacin and 
ofloxacin, both second-generation fluoroquinolones, have been used since the 1990s to treat 
patients with bacterial keratitis (5).   
1.7 PCR AS A DIAGNOSTIC TOOL 
Culture is the gold standard when it comes to identifying the pathogen that has invaded a 
patient’s cornea.  In the past two decades, researchers have been utilizing PCR and determining 
different assays that may be able to produce equal or better sensitivity values than results from 
culture.  Culture-based testing may take a few days to grow out properly on an agar plate for 
identification; therefore, PCR would be very helpful because results could be available in a few 
hours or at least in 18 to 24 hours (17).  For example, a real-time PCR assay developed to 
identify bacterial DNA from biological fluid samples is capable of having a result in about four 
hours by utilizing melting-curve analysis to distinguish between different bacteria (16).   Specific 
genes are targeted in these PCR assays, as well as different regions of the highly conserved 
universal 16S rRNA gene present in all bacterial species.  By having species-specific genes as 
targets in a PCR assay, a patient sample could be screened for these genes, in order to identify if 
that particular pathogen is at the source of the infection.  Also, universal primers would be able 
to determine if the infection is being caused by a bacterial source; moreover, if the PCR results 
are negative, then a bacterial pathogen could be ruled out and more tests could be run to 
determine the identity of the pathogen, whether it be viral or fungal, etc.  Other advantages of 
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using PCR are that the materials necessary for these assays are relatively inexpensive and have a 
long shelf life (17). Also, since small amounts of reagents are used in each run and small 
amounts of sample are used, materials will last longer and samples can be saved for later testing. 
 Aside from hardware expense, risk of contamination is the main disadvantage of PCR.  
The following steps can be taken by researchers to try and prevent contamination: placing 
collection materials, microcentrifuge tubes, pipettes, pipette tips, reagents, and water under UV 
light; using a laminar-flow hood rather than a benchtop; and using separate rooms for different 
steps in the PCR process (17).  Also, purchasing reagents and consumables that have been 
treated for nucleic acid contamination is another good laboratory practice to prevent 
contamination. 
1.8 REAL-TIME PCR ASSAYS 
Real-time PCR differs from conventional PCR by detecting the presence of amplified product in 
“real time” with the aid of a fluorescent molecule, as opposed to running amplified product on an 
agarose gel (4).  In addition to sequence-specific primers, the TaqMan assay utilizes a specific 
probe, which possesses a fluorescent reporter at the 5’ end and a quencher at the 3’ end (Figure 
2).  The probe binds to the specific DNA sequence during the annealing PCR stage.  Once the 
extension stage has been reached, the reporter is cleaved after a slight adjustment in the probe’s 
position.  Once cleaved, the reporter fluoresces; therefore, the amount of fluorescence is 
proportional to the amount of amplified DNA.  This assay is highly specific, but a drawback is 
that the probe used in this assay is very expensive, making this assay more costly than other PCR 
assays (4).    
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Figure 2. TaqMan assay (4). 
 
An alternative to using a probe, the SYBR Green assay utilizes a DNA-binding dye, 
which binds nonspecifically to double-stranded DNA.  When this dye is not bound to DNA, it 
does not fluoresce (Figure 3).  Moreover, the fluorescence increases up to 1,000-fold once SYBR 
Green binds to double-stranded DNA (4).  The fluorescence recorded by the real-time PCR unit 
is proportional to the amount of double-stranded DNA in the sample.  This assay provides a 
melt-curve analysis option unlike the TaqMan assay, which helps to determine if nonspecific 
products were amplified.  Unlike the TaqMan assay, SYBR Green is not as specific because the 
dye will bind to any double-stranded DNA present, while the probe in the TaqMan assay will 
only bind to a specific portion of DNA (4).   
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Figure 3. SYBR Green PCR assay (4). 
1.9 EVALUATION OF PCR AS A DIAGNOSTIC TOOL 
Five different descriptive statistics can be determined following a real-time PCR assay, which 
can be used for comparison against another diagnostic tool, such as culture.  In this study, 
sensitivity refers to how well the PCR works at detecting samples that are true positive and how 
well the assay limits the occurrence of false negative results.  Specificity values focus on the 
samples that should be true negatives in the assay and shows how well the PCR limits false 
positive results.  Positive predictive value takes into account the occurrence of true positives and 
false positives, while negative predictive value focuses on true negative values and false negative 
values.  The last calculation that can be used as comparison between PCR assays and diagnostic 
tools is efficiency, which takes into account true positives, true negatives, false positives, and 
false negatives, in order to determine how well the assay works overall (36). 
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The following shows how these calculations were mathematically determined: 
Sensitivity = [True Positive / (True Positive + False Negative)] x 100% 
Specificity = [True Negative / (True Negative + False Positive)] x 100% 
Positive Predictive Value = [True Positive / (True Positive + False Positive)] x 100% 
Negative Predictive Value = [True Negative / (True Negative + False Negative)] x 100% 
Efficiency = [(True Positive + True Negative) / (True Positive + False Positive + True Negative  
           + False Negative)]  
 
*True Positive = of the “true positives”, how many came up positive in PCR assay 
*False Negative = of the “true positives”, how many came up negative in PCR assay and  
                              supposed to be positive 
 
*True Negative = of the “true negatives”, how many came up negative in PCR assay 
*False Positive = of the “true negatives”, how many came up positive in PCR assay and  
                            supposed to be negative 
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2.0  GOALS AND SPECIFIC AIMS 
The main goal of this project was to determine if PCR was capable of detecting P. aeruginosa 
from corneal specimens of bacterial keratitis patients.  The Cepheid SmartCycler® II system 
(Sunnyvale, CA) was the real-time PCR system utilized in this project.  Two PCR targets for two 
different real-time PCR assays were selected for detection of P. aeruginosa, one being the 
species-specific ecfX gene, and the other the bacterial 16S rRNA gene, which is highly conserved 
in prokaryotes.  The ecfX gene is specific to P. aeruginosa and encodes an extracytoplasmic 
function sigma factor; moreover, this gene might act as a virulence factor or assist in haem-
uptake (21).  Specific primers and probe targeted at the ecfX gene, as well as universal primers 
and probe targeted at the 16S rRNA gene, were utilized in both PCR assays with the hope that 
they will detect P. aeruginosa from corneal specimens. 
2.1 SPECIFIC AIM 1: TO ESTABLISH A SPECIFIC REAL-TIME PCR ASSAY TO 
DETECT PSEUDOMONAS AERUGINOSA 
To establish this real-time PCR assay, the ecfX gene was cloned into a plasmid vector, followed 
by a plasmid dilution assay, in order to optimize the specific assay on the Cepheid SmartCycler® 
II real-time PCR system.  The optimization of the assay allowed for the determination of 
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amplification efficiency and limit of detection.  Once optimized, this real-time PCR assay was 
tested against P. aeruginosa isolates and non-P. aeruginosa isolates. 
2.2 SPECIFIC AIM 2: TO DETERMINE A SECONDARY TARGET FOR 
PSEUDOMONAS AERUGINOSA THAT MAY PROVIDE A UNIVERSAL TARGET FOR 
OTHER BACTERIAL PATHOGENS 
To establish this real-time PCR assay, the 16S rRNA gene was cloned into a plasmid vector, 
followed by a plasmid dilution assay, in order to optimize this assay on the Cepheid 
SmartCycler® II real-time PCR system.  The optimization of the assay allowed for the 
determination of amplification efficiency and limit of detection.  Once optimized, this real-time 
PCR assay was tested against P. aeruginosa isolates. 
2.3 SPECIFIC AIM 3: TO VALIDATE BOTH ASSAYS FOR DIAGNOSTIC 
TESTING WITH TRUE POSITIVE AND TRUE NEGATIVE CLINICAL SAMPLES 
Validation of both real-time PCR assays took place utilizing retrospective, excess de-identified 
ocular samples from patients with P. aeruginosa keratitis.  Amplified PCR products were 
purified and subjected to restriction digestion, in order to confirm the presence of amplified 
product.  The presence of amplified product was observed using PAGE analysis.  Descriptive 
statistics were determined to assess these two real-time PCR assays. 
 
 14 
3.0  MATERIALS AND METHODS 
3.1 CONTAMINATION CONTROL 
P. aeruginosa is a ubiquitous organism that has the ability to live in different types of 
environments, including the clinical laboratory; therefore, steps to prevent contamination were 
taken before experimentation.  The laminar flow hood was sprayed down with DNAZap™ 
(Ambion, Austin, TX) prior to handling the isolates or direct patient samples.  DNAZap™ 
consists of two different solutions, that when used together, have the ability to degrade 
contaminating DNA and RNA from surfaces (2).  The barrels of the pipettors were also sprayed 
down with DNAZap™ prior to handling.  When not in use, the laminar flow hood and contents 
of the hood were exposed to UV light. 
3.2 REAL-TIME PCR PRIMERS AND PROBE SETS 
The primers and probe sets utilized in the real-time PCR assays are listed in Table 1.  The set 
targeted for the 63 bp ecfX gene was found in the literature (3) and then ordered through 
Integrated DNA Technologies (IDT) (Coralville, IA).  All forward and reverse primers were 
used at a concentration of 0.4 µM and the Taqman probe was used at a concentration of 0.2 µM. 
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 The 16S rRNA 27F primer and probe set with a target size of 567 bp was used (32).  
MultAlin (6) software was used to design the forward primer F2, in order to produce a smaller 
target size of 144 bp and to have a forward primer that would work with the reverse primer and 
probe from the 27F set.  The F2 forward primer was ordered from IDT.  The BAK11W/BAK2 
primer set was found in the literature (44) and then ordered through IDT, to provide another 
primer set that would amplify a 792 bp section of the 16S rRNA gene.  All forward and reverse 
primers were used at a concentration of 0.4 µM and the Taqman probe was used at a 
concentration of 0.2 µM.   
3.3 PLASMID DNA PREPARATION FOR OPTIMIZATION OF REAL-TIME PCR 
ASSAYS 
In order to optimize the real-time PCR assays, a plasmid was constructed with the targeted genes 
of interest, the ecfX gene and the 16S rRNA gene.  The plasmid containing the ecfX gene, 
pMQ236/PA1300, was constructed by Eric Kalivoda, from the lab of Robert Shanks, Ph.D. (34).   
The plasmid containing the 16S rRNA gene, pGEM®-T Easy/PA UNI, was constructed with the 
pGEM®-T Easy Vector System (Promega Corporation, Madison, WI), following the pGEM®-T 
Easy Vector System Protocol (Promega, Corporation, Madison, WI).  
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3.4 DETERMINATION OF AMPLIFICATION EFFICIENCY AND LIMIT OF 
DETECTION 
Amplification efficiency refers to how well the real-time PCR unit is able to double one piece of 
DNA in each PCR cycle.  Results from plasmid dilution assays allow for amplification efficiency 
of a real-time PCR assay to be calculated; therefore, the ecfX primer set and the F2 16S rRNA 
primer set from this study were used to detect the target genes in the constructed plasmids at 
varying dilution values.  The ecfX specific primers and probe set directed at the ecfX gene were 
run against dilutions ranging from 10-3 to 10-9 of the pMQ236/PA1300 plasmid.  The F2 primer 
set and probe targeted at the 16S rRNA gene were run against dilutions ranging from 10-3 to 10-9 
of the pGEM®-T Easy/PA UNI plasmid.  Regression analysis was performed using Minitab 10 
statistical software (Minitab Inc., State College, PA) after recording the results from the plasmid 
dilution assays.  Amplification efficiency was determined using the equation E = 10(-1/slope) – 1, 
with the slope referring to the slope of the regression line, designated as the coefficient value 
next to ‘X’ in the y = b +aX equation.  Amplification efficiency values between 90% and 105% 
are considered to be in the acceptable range (4).  Limit of detection values were calculated next 
using the following template: 
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   Size of vector (bp) 
+ 
   X (bp) 
Size of insert (bp) 
 
1.0 A260 units ds DNA = 50 µg/ml 
 
O.D. = X2 
 
X2 x 50 x 80 = X3 µg/ml 
 
X3 µg/ml = Y ng/µl 
 
1 µg of 1000 bp is 9.1 x 1011 molecules  
 
1 µg of X DNA is: (9.1 x 1011) / (X-3) = Z molecules (copy number per µg) 
 
Per 1 µl of DNA = Z-3 x Y ng/µl = A molecules 
 
Dilution Factor: A x 1/ (lowest dilution amplified) = B copies/µl 
3.5 PREPARATION OF ISOLATES AND DIRECT SAMPLES PRIOR TO REAL-
TIME PCR ASSAYS 
3.5.1 P. aeruginosa Isolates and Positive Control Isolate 
The specific real-time PCR assay for the ecfX gene and the real-time PCR assays for the 16S 
rRNA gene should be able to detect P. aeruginosa isolates.  To test this we used DNA from 
retrospective, de-identified clinical isolates, which were part of a clinical bank.  These isolates 
were used for validation and susceptibility monitoring, and were stored at -80°C.  P. aeruginosa 
strain, ATCC 27853, was purchased from the American Type Tissue Collection and was used in 
both real-time PCR assays as a positive control.  In addition to the ATCC control, 21 de-
identified P. aeruginosa isolates were selected for the study.   
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3.5.2 Non-P. aeruginosa Isolates 
The specific PCR assay for the ecfX gene found in P. aeruginosa should not be able to detect any 
non-P. aeruginosa isolates, since the ecfX gene is specific to P. aeruginosa.  All retrospective, 
de-identified clinical isolates were part of a clinical bank, which is used for validation and 
susceptibility monitoring, and were stored at -80°C. 
The following are the 35 de-identified (use for validation and susceptibility monitoring) 
non-P. aeruginosa isolates that were selected for the study: Chlamydia trachomatis, Nocardia 
farcinica, Mycobacteria chelonae, Propionibacterium acnes, Bacillus species, Staphylococcus 
aureus, Streptococcus pneumoniae, alpha haemolytic streptococcus, nutritionally variant 
streptococcus, Enterococcus faecalis, Haemophilus influenzae, Moraxella lacunata, Escherichia 
coli, Serratia marcescens, Enterobacter aerogenes, Klebsiella oxytoca, Acinetobacter baumanii, 
Stenotrophomonas maltophilia, Deltfia acidovorans, Achromobacter xylosoxidans, 
Chryseobacterium indologenes, Chryseobacterium meningosepticum, Ochrobacterium anthropi, 
Pseudomonas putida, Pseudomonas fluorescens, and Burkholderia cepacia.  Fungal isolates, 
Candida parapsilosis, Candida albicans, Aspegillus niger, Alternaria species, and Fusarium 
species, were included as negative controls, in addition to free-living amoeba Acanthamoeba and 
Hartmanella species.  Lastly, adenovirus (ADV) and herpes simplex virus (HSV) type 1 were 
utilized as negative controls, as well.   
3.5.3 Direct Sample Collection 
All retrospective, de-identified clinical samples were part of a clinical bank, which is used for 
validation and susceptibility monitoring, and collected as excess specimens.  No additional 
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specimens were collected for this study.  These samples, stored at -80°C, were collected for 
bacterial culture and/or viral testing.  A sterile swab (Fisher Scientific, Houston, TX) or a kimura 
spatula were used to obtain corneal samples from patients, which were then added to 2.0 ml of 
Chlamydial Transport medium (Bartels, Bellevue, WA). 
3.5.4 Preparation of De-identified Samples   
A total of 40 de-identified patient samples were used in this study, following the establishment of 
both real-time PCR assays with P. aeruginosa and non-P. aeruginosa isolates.  20 true positives 
consisted of direct samples from the corneas of patients with keratitis that had P. aeruginosa 
isolated.  20 true negatives consisted of samples that did not have P. aeruginosa isolated; instead, 
these samples were spiked with these non-bacterial isolates: VZV, HSV, Fusarium species, 
Candida albicans, and Aspergillus niger.  All of these samples were extracted using the 
EPICENTRE® extraction technique and were then run against both the specific ecfX 
primers/probe set and the F2 primers/probe set.  Descriptive statistics were determined for both 
the ecfX gene PCR assay and the bacterial 16S rRNA gene PCR assay.    
3.6 DNA EXTRACTION 
The DNA from the P. aeruginosa and non-P. aeruginosa isolates, in addition to the de-
identified, direct patient samples, had to be extracted prior to both real-time PCR assays, and 
different DNA extraction methods were utilized.  The isolates were subjected to DNA extraction 
techniques in order to remove the DNA from the P. aeruginosa bacterial cells.  Also, DNA 
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extraction removed fluorescein, a fluorescent dye present in the direct patient samples, which 
would have interfered with the fluorescent activity of the TaqMan probe in the real-time PCR 
assays.  
3.6.1 Basic Heat Treatment Method 
DNA from P. aeruginosa isolates was extracted using the DNA extraction protocol used in 
previous work (3).  Bacterial colonies were grown out on blood agar plates and then a 1.0-
McFarland suspension in sterile, nuclease-free water was carried out for each isolate.  The 
suspensions were then placed in a heating block set at 100.0ºC for a 10 minute time period.  Each 
suspension was then vortexed and centrifuged at 3000 rpm for 5 minutes.  All of the suspensions 
were stored at -20ºC. 
3.6.2 QIAamp DNA Mini Kit extraction 
For the QIAamp DNA Mini Kit extraction protocol, P. aeruginosa colonies were selected from 
blood agar plates with an inoculation loop and then suspended in 180 µl of Buffer ATL.  The 
loops were stirred several times in the buffer, in order to thoroughly suspend the bacteria 
colonies.  20 µl of Proteinase K was added to each suspension, followed by vortexing and 
incubation in a heating block at 56ºC for 3 hours.  Following this lysis incubation period, the 
tubes were centrifuged quickly and then 200 µl of Buffer AL were added to each tube.  All of the 
tubes were pulse-vortexed for 15 seconds and then incubated at 70ºC for 10 minutes.  Following 
this second incubation, the tubes were centrifuged again and then 200 µl of 100% ethanol were 
added.  All the tubes were pulse-vortexed for 15 seconds.  The mixtures in the tubes were added 
 21 
to individual QIAamp Spin Columns which each fit into a 2 ml collection tube.  The columns 
were spun at 8000 rpm for 1 minute.  The collection tubes were discarded, and the spin columns 
were placed into new collection tubes.  Following this step, 500 µl of Buffer AW1 were added to 
each spin column, which was then centrifuged at 8000 rpm for 1 minute.  The collection tubes 
were discarded, and the spin columns were placed into new collection tubes.  Then 500 µl of 
Buffer AW2 were added to each spin column, which was then centrifuged at 13,000 rpm for 3 
minutes.  The collection tubes were discarded, and the spin columns were placed into new 
collection tubes.  The tubes were then spun at 13,000 rpm for 1 minute.  The collection tubes 
were thrown away, and the spin columns were then placed into clean 1.5 ml microcentrifuge 
tubes.  Next, 100 µl of Buffer AE was added to each spin column twice, followed by a 5 minute 
incubation period at room temperature.  Then the tubes were centrifuged at 8000 rpm for 1 
minute.  The final 200 µl extraction solutions were stored at -20ºC. 
3.6.3 EPICENTRE® Extraction Technique 
For the non-P. aeruginosa isolates, a 0.5-McFarland suspension of each isolate was carried out.  
Next, 300 µl were aliquoted, heated at 98ºC for 10 minutes, and put on ice for a few minutes, 
followed by the addition of  150 µl of MPC protein precipitation solution (EPICENTRE, 
Madison, WI).  Each tube was vortexed for 10 seconds and then centrifuged at 10,000 rpm for 10 
minutes at 4ºC.  The supernatant from each tube was decanted into a clean tube that contained 
500 µl of isopropanol (DNase, RNase, Protease free) (Acros Organics, Fisher Scientific, 
Pittsburgh, PA).  Each new tube was inverted 30 to 40 times and then centrifuged at 10,000 rpm 
for 10 minutes at 4ºC.  Following centrifugation, the supernatants in each tube were discarded, 
with 500 µl of 75% ethanol (Spectrum Chemical Mfg. Corp., Gardena, CA) being added to each 
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pellet.  All tubes were spun and centrifuged at 10,000 rpm for 5 minutes at 4ºC.  Then 500 µl of 
75% ethanol was added to the pellets again and centrifuged at the same settings.  The 
centrifugation step was followed by a 30 to 45 minute drying stage for the pellets using a 
vacuum system.  After drying, the pellets were suspended in 35 µl of TE buffer (10mM Tris-
HCL [pH 8.0], 1 mM EDTA, Epicentre, Madison, WI). 
Direct patient samples were also extracted using the EPICENTRE® DNA extraction 
technique (Epicentre, Madison, WI) described above.  The only change in the protocol that was 
implemented was that the final pellets were suspended in 45 µl of TE buffer rather than 35 µl, in 
order to utilize and store more extracted DNA from the samples. 
3.7 SMARTCYCLER® II REACTION MIX 
The Cepheid SmartCycler® II Real-Time PCR system (Sunnyvale, CA) was used for all real-time 
PCR runs, in addition to 25 µl SmartCycler® II tubes.  The PCR reactions using the primers and 
probe targeted at the ecfX gene consisted of 18.1 µl of master mix and 6.9 µl of sample.  The 
master mix used in this assay consisted of a forward primer, reverse primer, probe, and TaKaRa 
Premix Ex Taq (Otsu, Shiga, Japan).  The concentration of the primers used in all of the different 
real-time PCR reactions was set at 0.4 µM, with probe concentration set at 0.2µM. 
The PCR reactions for the 27F and F2 16S rRNA primers and probe sets consisted of 
17.5 µl of master mix and 7.5 µl of sample.  The master mix used in these assays consisted of a 
forward primer, reverse primer, probe, and TaKaRa Premix Ex Taq™ (Otsu, Shiga, Japan).  The 
PCR reactions utilizing the BAK11W/BAK2 primer set consisted of 20.0 µl and 5.0 µl of 
sample.  The master mix used in these reactions consisted of a forward primer, reverse primer, 
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DNAase-free water, and TaKaRa SYBR® Premix Ex Taq™ (Otsu, Shiga, Japan).  The 
concentration of the primers used in all of the different real-time PCR reactions was set at 0.4 
µM, with probe concentration set at 0.2µM. 
3.8 SMARTCYCLER® II PCR THERMAL CYCLING 
The PCR settings for the ecfX gene specific real-time PCR assay were set at the following 
parameters:  Stage 1) 95.0°C for 900 seconds; Stage 2) 45 cycles at 95.0°C for 15 seconds and 
60.0°C for 60 seconds. 
The PCR settings for the 16S rRNA gene assays, involving the 27F and F2 primer sets, 
were optimized at the following parameters:  Stage 1) 95.0°C for 900 seconds; Stage 2) 45 cycles 
at 95.0°C for 15 seconds and 60.0°C for 30 seconds.  The PCR settings for the 16S rRNA gene 
assay involving the BAK11W/BAK2 primer set were optimized at the following parameters:  
Stage 1) 95.0ºC for 60 seconds; Stage 2) 40 cycles at 95.0ºC for 60 seconds, 51.0ºC for 60 
seconds, and 72.0ºC for 35 seconds; and Stage 3) melt curve analysis. 
3.9 AMPLIFIED PCR PRODUCT PURIFICATION 
Before subjecting the amplified PCR products (from the de-identified patient samples) to 
restriction digestion and PAGE analysis, they first had to be purified to remove the primers and 
other impurities, in order to isolate the DNA.  The QIAGEN QIAquick PCR Purification kit 
(Valencia, CA) was used to purify the amplified product from 15 true positive patient samples 
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from the ecfX gene assay and amplified product from the 14 true positive patient samples with 
the 16S rRNA gene assay.  The protocol used can be found under the QIAquick PCR 
Purification Kit Protocol (using a microcentrifuge).  Prior to using this kit, PCR products were 
transferred from the Smartcycler reaction tubes to a 1.5 ml Sarstedt tube (SARSTEDT Inc., 
Newton, NC).  Quantities were measured for each patient sample.  For each volume of PCR 
product isolated from the Smartcycler reaction tubes, five volumes of Buffer PB were added and 
mixed with each sample.  The resulting solution was then transferred to a QIAquick spin column, 
which sat in a 2 ml collection tube.  At room temperature, the spin columns were centrifuged at 
13,000 rpm for one minute.  The collection tubes were discarded and replaced with new 2 ml 
collection tubes.  Then 750µl of Buffer PE were added to each column and centrifuged for one 
minute.  The collection tubes were again discarded and replaced with new 2 ml collection tubes.  
The spin columns were centrifuged for another minute, in order to remove any residual ethanol.  
Spin columns were then removed from the collection tubes and placed into 1.5 ml 
microcentrifuge tubes.  30µl of DNAse free water were added to each sample and then were left 
in the hood for at least one minute, followed by centrifuging for one minute.  The purified DNA 
samples were then stored at -20°C. 
3.10 RESTRICTION DIGESTION OF AMPLIFIED PCR PRODUCTS 
In order to confirm that the amplified PCR products (from the de-identified patient samples) in 
the real-time PCR assays were the expected amplified PCR products, restriction enzyme 
digestion was carried out.  NEBcutter V2.0 (New England BioLabs, Inc. software) was used to 
determine the available restriction enzyme site options for the 63 bp ecfX gene target.  The ecfX 
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gene target purified PCR products from the de-identified patient samples were cut with the 
restriction enzyme, NcoI (New England BioLabs, Inc. software), in order to obtain 44 bp and 19 
bp fragments as predicted for the ecfX amplicon.  The reaction consisted of the following 
reagents: 10 µl of DNA; 2 µl of Buffer 4; 7.5 µl of distilled water; and 0.5 µl of NcoI.  Reactions 
were incubated overnight in a waterbath at 37°C to ensure full digestion.   
NEBcutter V2.0 (New England BioLabs, Inc. software) was used to determine the 
available restriction enzyme site options for the 144 bp 16S rRNA gene target.  The 16S rRNA 
gene target purified PCR products from the patient samples were cut with the restriction enzyme, 
SacII (New England BioLabs, Inc. software), in order to obtain 97 and 47 bp fragments as 
predicted for the amplicon.  The reaction consisted of the following reagents: 10 µl of DNA; 2 µl 
of Buffer 4; 7.5 µl of distilled water; and 0.5 µl of SacII.  Again, reactions were incubated 
overnight in a waterbath at 37°C to ensure full digestion. 
3.11 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE) 
After the amplified PCR products had undergone restriction digestion overnight, they were 
subjected to PAGE analysis.  15% polyacrylamide gels were poured and positive control P. 
aeruginosa samples (ATCC 27853) were loaded to validate the presence of the 63 bp ecfX gene 
target, as well as the expected restriction digest patterns from the 15 positive patient samples. 
A 15% and a 6% polyacrylamide gel were poured and positive control P. aeruginosa 
samples (ATCC 27853) were loaded to validate the presence of the 144 bp 16S rRNA gene 
target, as well as the expected restriction digest patterns.  For these larger restriction digest 
fragments, a 6% gel was poured instead of a 15% for the de-identified patient sample amplified 
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PCR products, in order to allow for better visualization and separation on the gel; therefore, to 
analyze the 14 positive patient samples, 6% polyacrylamide gels were poured.  All gels were run 
at 100V, ranging from 90 to 120 minutes in duration, and were stained with 10 µl of ethidium 
bromide prior to image collection using a Gel Logic Imaging System (Carestream Health 
Molecular Imaging, Woodbridge, CT).            
 27 
4.0  RESULTS 
4.1 AMPLIFICATION EFFICIENCY AND LIMIT OF DETECTION 
In order to optimize the ecfX real-time PCR assay, the ecfX primers and probe were used against 
serial dilutions of the pMQ236/PA1300 plasmid construct.  The lowest dilution value that was 
detected by the real-time PCR assay was used in the calculation of the amplification efficiency.  
The ecfX primer set detected the ecfX plasmid in a serial dilution ranging from 10-3 to 10-9, 
during the specific ecfX gene PCR assay, which lasted for a 45 cycle duration (Figure 4).  A 
sigmoidal, S-shaped curve appeared for each dilution value, which is a visual sign of an efficient 
real-time PCR reaction.  The Ct values ranged from 18.51 to 38.67, with a cycle difference of 
about 3 between each measured dilution value (Table 2).   
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Figure 4. Plasmid dilution assay of real-time P. aeruginosa ecfX PCR Assay.  
Optimization of the ecfX real-time PCR assay was determined using a plasmid dilution assay.  Serial  
dilutions of the pMQ236/PA1300 plasmid were performed, ranging from 10-3 to 10-9.  Each dilution was 
performed in duplicate, in addition to the negative control (TE buffer), and were subjected to the ecfX PCR 
assay (45 cycles). The Ct values for the serial dilutions ranged from 18.51 to 38.67, with a cycle difference 
of about 3 between each measured dilution value.  The negative control was not detected by real-time PCR.    
 
The recorded Ct values at each dilution factor were plotted versus the set dilutions on a 
regression plot (Figure 5).  The slope of this regression plot, a value of -3.40611, allowed for the 
calculation of an amplification efficiency of 0.966 or 96.6%.  From this data, the limit of 
detection was calculated to be 33.6 copies of target DNA/µl.   
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Figure 5. Real-time P. aeruginosa ecfX PCR Assay Regression Analysis.  
Data obtained from the pMQ236/PA1300 plasmid dilution assay was used to produce a regression plot on 
Minitab 10 statistical software (Minitab Inc., State College, PA), with Ct values versus dilution values. The 
slope of the regression line was calculated to be -3.40611, with an R-square value of 99.9%.  This slope 
value was used in the calculation of the amplification efficiency value, which was determined to be 96.6%.  
 
 In order to optimize the ecfX real-time PCR assay, the ecfX primers and probe were used 
against serial dilutions of the pGEM®-T Easy/PA UNI plasmid plasmid construct.  The 16S 
rRNA primer set detected the 16S rRNA plasmid in a serial dilution ranging from 10-4 to 10-9 
during the 16S rRNA gene PCR assay, which lasted for a 45 cycle duration (Figure 6).  A 
sigmoidal, S-shaped type curve was present at each dilution value.  The Ct values ranged from 
18.89 to 35.69, with a cycle difference of about 3 between each measured dilution value (Table 
2).     
 30 
 
Figure 6. Plasmid dilution assay of real-time bacterial 16S rRNA PCR Assay.  
Optimization of the F2 16S rRNA real-time PCR assay was determined using a plasmid dilution assay.  
Serial dilutions of the pGEM®-T Easy/PA UNI plasmid were performed, ranging from 10-4 to 10-9.  Each 
dilution was performed in duplicate, in addition to the negative control (TE buffer), and were subjected to 
the ecfX PCR assay (45 cycles). The Ct values for the serial dilutions ranged from 18.89 to 35.69, with a 
cycle difference of about 3 between each measured dilution value.  The negative control was not detected 
by real-time PCR.    
 
 
The recorded Ct values at each dilution factor were plotted versus the set dilutions on a 
regression plot (Figure 7).  The slope of this regression plot, a value of -3.24314, allowed for the 
calculation of an amplification efficiency of 1.034, or 103.4%.  From this data, the limit of 
detection was calculated to be 8.12 copies of target DNA/µl.   
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Figure 7. Real-time bacterial 16S rRNA PCR Assay Regression Analysis.  
Data obtained from the pGEM®-T Easy/PA UNI plasmid dilution assay was used to produce a regression 
plot on Minitab 10 statistical software (Minitab Inc., State College, PA), with Ct values versus dilution 
values. The slope of the regression line was calculated to be -3.24314, with an R-square value of 100.0%.  
This slope value was used in the calculation of the amplification efficiency value, which was determined to 
be 103.4%.  
4.2 REAL-TIME PCR ASSAYS WITH P. AERUGINOSA AND NON-P. AERUGINOSA 
ISOLATES 
To test whether the ecfX primer set would detect P. aeruginosa and to test whether this primer 
set would not detect non-P. aeruginosa isolates, we performed the ecfX real-time PCR assay on 
the 21 P. aeruginosa isolates and 35 non-P. aeruginosa isolates.  Following the DNA extraction 
protocols, it was found that 100% of the P. aeruginosa keratitis isolates (n=21) were detected 
with the ecfX real-time PCR assay, while none of the non-P. aeruginosa bacterial, fungal, 
amoeboid, and viral keratitis isolates (n=35) were detected (Figure 8).  
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Figure 8. P. aeruginosa positive isolates from ecfX and bacterial 16S rRNA real-time PCR assays.  
All 21 P. aeruginosa isolates were detected by both real-time PCR assays.  The 35 non-P. aeruginosa  
isolates were not detected by the ecfX real-time PCR assay.  The F2 primer set was used in the 16S rRNA 
real-time PCR assays. The negative controls (TE buffer) in each PCR run were not detected by the primer 
sets.  The isolates that were detected by the assays produced similar Ct values to the positive control P. 
aeruginosa strain (ATCC 27853). 
 
To test whether the 16S rRNA primer sets (Table 1) would detect P. aeruginosa, we 
performed the 16S rRNA real-time PCR assay on the 21 P. aeruginosa isolates.  100% of the P. 
aeruginosa keratitis isolates (n=21) were detected using the 27F primer set in this real-time PCR 
assay (32).  After deriving the F2 forward primer from the MultAlin (6) software to be used with 
the 27F reverse primer and probe (32), 100% of the P. aeruginosa keratitis isolates (n=21) were 
detected with this real-time PCR assay (Figure 8).  Twenty-one P. aeruginosa positive keratitis 
isolates were detected using the BAK11W/BAK2 primer set (44).  In addition to these isolates, 
22 non-P. aeruginosa positive keratitis isolates were detected using this assay.     
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4.3 REAL-TIME PCR ASSAYS OF DE-IDENTIFIED PATIENT SAMPLES 
4.3.1 P. aeruginosa ecfX gene PCR assay results 
To test whether the ecfX primer set would detect P. aeruginosa from direct patient samples, we 
performed this assay on twenty true positive and twenty true negative de-identified patient 
samples.  Fifteen of the twenty true positive de-identified patient samples tested were detected as 
positive for P. aeruginosa in the ecfX specific real-time PCR assay.  Each of the positive 
samples’ real-time data showed a sigmoidal, S-shaped curve, which is an observational cue that 
the real-time PCR assay is working optimally (Figure 9).  Ct values of these positive samples 
ranged from 24.89 cycles up to 44.86 cycles, out of a total of 45 cycles.  This assay produced an 
efficiency value of 85%, sensitivity value of 75%, and specificity value of 95% (Table 4). 
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Figure 9.  Keratitis de-identified patient samples P. aeruginosa ecfX PCR assay.  
Fifteen of the twenty de-identified true positive patient samples were detected by the ecfX real-time PCR 
assay and include the following: 9893, 9516, 9742 (a.); T39, T44, T157 (b.); 9956 (c.); 8834, 9402, 9748 
(d.); 9495, 9551 (e.); 9398, 9691 (f.); T273 (g.). The positive control P. aeruginosa strain (ATCC 27853) 
was also detected and depicted in each panel. The real-time data shows the sigmoidal, S-shaped curve, and 
Ct values for all samples ranged from 24.89 cycles up to 44.86 cycles, out of a total of 45 cycles. 
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4.3.2 Bacterial 16S rRNA gene PCR assay results 
To test whether the F2 primer set would detect P. aeruginosa from direct patient samples, we 
performed this assay on twenty true positive and twenty true negative de-identified patient 
samples.  Fourteen of the twenty true positive patient samples tested were detected as positive for 
P. aeruginosa in the 16S rRNA gene real-time PCR assay.  Each of the positive samples’ real-
time data showed a sigmoidal, S-shaped curve or close resemblance to this type of curve (Figure 
10).  Ct values of these positive samples ranged from 25.04 cycles up to 39.41 cycles, out of a 
total of 45 cycles.  This assay produced an efficiency value of 85%, sensitivity value of 70%, and 
specificity value of 100% (Table 4). 
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Figure 10. Keratitis de-identified patient samples 16S rRNA assay.  
Fourteen of the twenty de-identified true positive patient samples were detected by the F2 16S rRNA real-
time PCR assay (TaqMan) and include the following: 9893, 9742 (a.); T39, T44, T157 (b.); 9956 (c.); 
8834, 9402, 9748 (d.); 9551 (e.); 9398, 9691 (f.); 9328, T273 (g.). The positive control P. aeruginosa strain 
(ATCC 27853) was also detected and depicted in each panel. The Ct values for all samples ranged from 
25.04 cycles up to 39.41 cycles, out of a total of 45 cycles.  
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4.3.3 Validation of real-time PCR using PAGE analysis 
To show that the amplified products from the de-identified patient samples in the ecfX real-time 
PCR assay were in fact the expected product sizes, we performed purification of these PCR 
products, followed by restriction digests with NcoI and PAGE analysis.  In Figure 11, the 
positive control showed the expected 63 bp band on a 15% polyacrylamide gel in lanes 1, 3, and 
6 for the ecfX  real-time assay.  Lanes 2, 4, and 7 showed the expected digest patterns with a 44 
bp and a 19 bp band present in each lane (Figure 11).  A 25 bp DNA ladder was loaded and run 
in lane 5 on the gel.  
 
 
Figure 11. 15% polyacrylamide gel restriction digest of positive control P. aeruginosa (ATCC 27853) 
from ecfX assay.  
The positive control strain of P. aeruginosa (ATCC 27853) was subjected to restriction digestion with the 
restriction enzyme NcoI in triplicate, after undergoing purification of the amplified product from the ecfX 
assay. The purified samples were run on a 15% polyacrylamide gel and restriction digest patterns were 
observed after exposure to ethidium bromide. Lanes 1, 3, and 6 showed the samples that were not cut with 
NcoI, while lanes 2, 4, and 7 showed the samples that were cut with NcoI. Lane 5 showed the 25 bp ladder 
used, with the 25, 50, and 75 bp bands marked. The uncut lanes showed the expected 63 bp fragment, while 
the cut lanes showed the expected 44 and 19 bp fragments.  
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In Figure 12, the fifteen ecfX purified PCR products from the patient samples that had 
come up as positive in the ecfX real-time PCR assay showed the presence of the expected 63 bp 
band, as seen in the positive control gel (Figure 11).  After being cut with the NcoI restriction 
enzyme, fourteen of the fifteen samples showed the expected restriction digest patterns, with the 
sample in lane 7 (top gel pictured) showing no signs of the 44 bp and 19 bp fragments (Figure 
12).   
 
 
 
 
 
 
 
 
 
 
 
 
 39 
 
 
Figure 12. 15% polyacrylamide g el res triction d igest o f de-identified patient s amples f rom P. 
aeruginosa ecfX assay.  
Of the 15 de-identified true positive patient samples that were detected by the ecfX real-time PCR assay, 15 
showed the expected 63 bp band, while 14 showed the expected 44 and 19 bp bands after being subjected 
to restriction digestion with NcoI. 9893 (lanes 2 and 3), 9516 (lanes 6 and 7), 9742 (lanes 8 and 9), T39 
(lanes 11 and 12), and T44 (lanes 13 and 14) in top gel. T157 (lanes 2 and 3), 9956 (lanes 4 and 5), 8834 
(lanes 7 and 8), and 9402 (lanes 9 and 10) in second gel from top. 9748 (lanes 2 and 3), 9495 (lanes 4 and 
5), 9551 (lanes 7 and 8), and 9398 (lanes 9 and 10) in third gel from top. 9691 (lanes 2 and 3) and T273 
(lanes 5 and 6) in bottom gel. The de-identified sample 9516, in lane 7 (top gel), did not show the expected 
44 and 19 bp bands.  
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To show that the amplified products from the de-identified patient samples in the 16S 
rRNA real-time PCR assay were in fact the expected product sizes, we performed purification of 
these PCR products, followed by restriction digests with SacII and PAGE analysis.  In Figure 13, 
the positive control showed the expected 144 bp band on a 15% polyacrylamide gel (lanes 2, 4, 
7, and 9 from the top gel pictured) and 6% polyacrylamide gel (lanes 2, 4, 7, and 9 from the 
bottom gel pictured).   In addition to these observations, the expected digest patterns with 97 bp 
and 47 bp bands were visible on the 15% gel (lanes 1, 3, 6, and 8) and 6% gel (lanes 3, 5, 8, and 
10).  A 25 bp DNA ladder was loaded and run in lanes 5 and 10 on the 15% gel (top gel) and in 
lanes 1 and 6 on the 6% gel (bottom gel).    
  
 
Figure 13. 15% and 6% polyacrylamide ge ls r estriction d igest of  p ositive c ontrol P. aeruginosa 
(ATCC 27853) from bacterial F2 16S rRNA assay.  
The positive control strain of P. aeruginosa (ATCC 27853) was subjected to restriction digestion with the 
restriction enzyme SacII (repeated eight times), after undergoing purification of the amplified product from 
the F2 assay. The purified samples were run on a 15% polyacrylamide gel (top gel) and a 6% 
polyacrylamide gel (bottom gel) and restriction digest patterns were observed after exposure to ethidium 
bromide. Lanes 5 and 10 (top gel) and lanes 1 and 6 (bottom gel) showed the 25 bp ladder used, with the 
25, 50, 75, 100, 125, and 150 bp bands marked in lane 6 (bottom gel). The uncut lanes, designated as (-) 
SacII, showed the expected 144 bp fragment, while the cut lanes, designated as (+) SacII, showed the 
expected 97 and 47 bp fragments.  
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In Figure 14, the fourteen 16S rRNA purified PCR products from the patient samples that 
had come up as positive in the 16S rRNA real-time PCR assay showed the presence of the 144 
bp band, as seen in the positive control gel (Figure 13).  All fourteen samples had the expected 
digest patterns, after being cut with the SacII restriction enzyme, showing the presence of a 97 
and a 47 bp fragment. 
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Figure 14. 6% polyacrylamide gel restriction digest o f de -identified patient samples from bacterial 
16S rRNA assay.  
Of the 14 de-identified true positive patient samples that were detected by the F2 16S rRNA real-time PCR 
assay, all 14 showed the expected 144 bp band, and the expected 44 and 19 bp bands after being subjected 
to restriction digestion with SacII. 9893 (lanes 2 and 3), 9742 (lanes 4 and 5), T39 (lanes 7 and 8), and T44 
(lanes 9 and 10) in top gel. T157 (lanes 2 and 3), 9956 (lanes 4 and 5), and 8834 (lanes 7 and 8) in second 
gel from top. 9402 (lanes 2 and 3), 9748 (lanes 4 and 5), 9551 (lanes 7 and 8), and 9398 (lanes 9 and 10) in 
third gel from top. 9691 (lanes 2 and 3), 9328 (lanes 4 and 5), and T273 (lanes 7 and 8) in bottom gel. 
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5.0  DISCUSSION 
 Culture is the primary diagnostic tool in determining the identity of the infectious pathogen 
linked to individual keratitis cases in patients, but PCR has provided laboratories with an 
additional way to confirm the etiology of a keratitis infection.  For example, in one study, 
isolates of P. aeruginosa were taken from patients with keratitis and subjected to PCR testing 
(35).  This PCR assay focused on amplifying the 367 bp exotoxin-A gene from P. aeruginosa 
isolates with specific primers (35).  It was concluded that PCR was a good complement to 
culture and biochemical tests in identification of pathogens (35).   Real-time PCR has become 
useful in detecting other corneal pathogens, such as Acanthamoeba (37).  Thompson et al. 
compared two different real-time PCR assays, Qvarnstrom and Rivière, and found that the 
Qvarnstrom assay was able to detect more Acanthamoeba genotypes than the Rivière assay (37).  
This group concluded that PCR testing should be used alongside cultures and smears, in order to 
identify corneal pathogens (37).       
In addition to common ocular pathogens, such as P. aeruginosa and Acanthamoeba, PCR 
has been used to identify more rare forms of these ocular pathogens involved in keratitis.  
Human cytomegalovirus is a difficult virus to study because since it is a species specific 
pathogen animal models are not ideal, although murine models have been used (14).  This virus 
causes ocular damage in infected patients and has been linked to keratitis; therefore, a study was 
performed utilizing real-time PCR as a tool to diagnosis CMV in keratitis patients (14).  Similar 
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to the ecfX PCR assay used in this study, this PCR assay had a small target size of 61bp and a 
TaqMan probe was utilized (14).  The real-time PCR results were able to help calculate copy 
number values, which decreased over time as patients continued receiving treatment for their 
infection (14).  Aside from CMV, PCR has also been used to detect microsporidial infections in 
keratitis patients (13).        
The ecfX gene has been shown to be a target for identification of P. aeruginosa (3, 21), 
but to our knowledge, not yet been tested against keratitis isolates and direct patient samples 
from the cornea.  In this study, 100% of the P. aeruginosa positive keratitis isolates tested were 
detected by the real-time ecfX PCR assay.  This species-specific gene based PCR assay did not 
detect any non-P. aeruginosa isolates.  In terms of testing direct de-identified patient samples, 
the ecfX primer set and specific probe produced a sensitivity of 75% and an efficiency of 85% 
(Table 4).  For a clinical diagnostic test, the desired values for sensitivity and efficiency are 
100%; therefore, future studies should further analyze the false negative samples.  It can be 
concluded that the 63 bp target amplified by the ecfX primer set with the specific probe was 
shown to be a potential target for detection of Pseudomonas aeruginosa DNA in keratitis 
patients, but further studies are needed to produce a more sensitive real-time ecfX PCR assay.     
Different studies have identified primer sets that have been considered universal, 
meaning that they have the ability to amplify a portion of the highly conserved 16S rRNA gene 
found in all bacterial species (26).  These types of PCR assays have been used in the studies of 
the following infections: bacteraemia (23); bacterial contamination of platelets (8, 27); central 
vascular catheters (39); bacterial meningitis (18, 33); and bacterial endocarditis (9).  More 
specifically, groups have started using these types of primer sets in keratitis research (17, 31).  
The 27F primer set was tested and was able to detect P. aeruginosa isolates through the 
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amplification of a 563 bp target; however, it was not effective at amplifying P. aeruginosa DNA 
extracted directly from the de-identified patient samples.  The F2 forward primer was then 
designed to work with the reverse primer and probe from the 27F primer set and to amplify a 
smaller portion of the 16S rRNA gene, since the recommended target size for optimal real-time 
PCR results is between 75 and 200 bp (4).  The 27F primer set was discontinued in the de-
identified patient study and was replaced by this F2 primer set, which amplified a 144 bp 
segment of the 16S rRNA gene. 
The F2 primer set had a sensitivity of 70% and efficiency value of 85% (Table 4).  For a 
clinical diagnostic test, the desired values for sensitivity and efficiency are 100%; therefore, 
future studies should further analyze the false negative samples.  Based on results from a SYBR 
Green real-time PCR assay, the F2 primer set was able to detect DNA from different bacterial 
species known to be common ocular pathogens (Table 3).  This primer set used with SYBR 
Green, rather than with a specific probe, should be further studied because this assay can detect 
non-specific amplified products in the reaction tubes through melt curve analysis.  Future testing 
of this primer set with bacterial species, aside from P. aeruginosa, will have to be performed.  It 
can be concluded that the 144 bp target amplified by the F2 primer set with the specific probe 
was shown to be a potential secondary target for detection of P. aeruginosa DNA in keratitis 
patients, but further testing must be carried out to produce a more sensitive real-time PCR assay.     
Following the de-identified patient sample study, the BAK11W/BAK2 primer set was 
tested because although the F2 primer set was able to detect P. aeruginosa from direct de-
identified patient samples, it was found in further testing that this set was not effective at 
detecting some DNA from other types of bacterial isolates (data not shown).  The real-time PCR 
assay results showed that the BAK11W/BAK2 primer set was able to detect 21 P. aeruginosa 
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isolates and 22 non-P. aeruginosa bacterial isolates.  Melt-curve analysis showed that the 
amplified products were pure, with no nonspecific products being amplified.  Even though the 
BAK11W/BAK2 set was able to detect P. aeruginosa and non-P. aeruginosa isolates, further 
testing of this primer set needs to be performed to evaluate how well this primer set will be able 
to amplify bacterial DNA from keratitis patient samples.   
Table 5 shows the expected and actual results from the ecfX real-time PCR assay and the 
16S rRNA PCR assay utilized in the de-identified patient study.  Actual results that differ from 
the expected results are italicized.  Seven different de-identified patient samples (9516; T192; 
T238; 9471; 9495; 9821; 9856; 9328) produced results that differed from the expected.  The only 
de-identified patient sample that was not detected by the ecfX assay was 9328.  The only de-
identified patient samples that were not detected by the 16S rRNA assay included 9516 and 
9495.  Patient samples T192, T238, 9471, and 9856 were not detected by either of the two real-
time PCR assays.  Since all four of these samples were not detected by either assay, the possible 
ineffective collection of the samples from patient corneas must be taken into consideration.  In 
addition to sampling error, the storage of the amplified PCR products and freeze-thaw issues 
could have affected the real-time PCR results.  Also, DNA could have been lost during the DNA 
extraction process, leading to a concentration lower than that of the calculated limit of detection.        
Aside from the issue of sample collection, another factor that was considered was PCR 
inhibition.  In order to eliminate this factor as a possible reason for false negative results, the five 
false negatives from the de-identified patient sample ecfX assay were tested.  Each of the five 
samples were spiked with a 10-4 dilution of the constructed ecfX plasmid and run against the ecfX 
real-time PCR assay.  All five samples were detected by the assay and positive results were 
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recorded.  This test showed that the PCR unit was working properly and that there were no 
inhibitors present during the de-identified patient study PCR assays. 
Concentration levels of bacterial DNA and human DNA had to be considered, as well, 
with the de-identified patient sample study.  The NanoDrop 2000 was utilized in measuring 
DNA concentrations of samples, but unfortunately, this machine did not have the ability to 
distinguish between bacterial and human DNA (Table 6).  The samples that were not detected by 
the PCR assays may not have had an adequate amount of bacterial DNA present, but may have 
had human DNA present, which would not have been detected by the primer sets.     
 Validation of the amplified PCR products was important to ascertain, in order to confirm 
that the real-time assays had amplified the expected PCR products.  All of the de-identified 
patient samples that had produced positive real-time PCR results in both assays underwent 
restriction digestion to confirm the positive result.  NEBCutter V2.0 (New England BioLabs, 
Inc.) mapped out the possible restriction enzyme sites for each gene target.  NcoI and SacII were 
selected based on the size of the fragments that would result following the restriction digests and 
the availability in the laboratory.  With such small amplified products sizes, PAGE analysis was 
used rather than going through the process of DNA sequencing; moreover, the amplified PCR 
products, due to their small size, would have to be cloned into a plasmid vector in order to 
produce DNA sequencing results.  All of the amplified PCR products tested from the de-
identified patient samples, except for one, showed the expected digest patterns, as compared to 
the positive controls.  An improperly setup restriction digest solution could have contributed to 
this one sample not cutting.  Also, with this sample, a possible mutation could have been 
introduced during the PCR amplification process or this particular strain of P. aeruginosa could 
have possessed a mutation, leading to a negative PCR result.    The presence of nonspecific 
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bands on the gels was observed with some of the patient samples, which could have been due to 
primer dimers.  
 49 
6.0  CONCLUSIONS AND PUBLIC HEALTH RELEVANCE 
In conclusion, real-time PCR provides clinical laboratories with a supplementary diagnostic tool 
to culture in the diagnosis of P. aeruginosa keratitis.  Species-specific primers and primers 
targeted at the 16S rRNA gene have the ability to detect bacterial DNA extracted from isolates 
and direct patient samples.  The ecfX real-time PCR assay (21) was adapted to the Cepheid 
SmartCycler® II real-time PCR system and was shown to detect P. aeruginosa isolates and P. 
aeruginosa from direct de-identified patient samples.  Universal primer real-time PCR assays 
targeting the highly conserved bacterial 16S rRNA gene, once validated, will be able to detect 
bacteria from the cornea that do not grow out in culture.  Although both assays detected different 
genes of P. aeruginosa, real-time PCR testing needs to produce higher sensitivity values for 
clinical diagnostic purposes.  Restriction digests and PAGE analysis are tools that can be used to 
validate results from real-time PCR assays, as used in this study.   
 In terms of public health relevance, this study was important because real-time PCR was 
shown to serve as a supplemental diagnostic tool to culture in P. aeruginosa related keratitis.  
Patient corneas that are pretreated with antibiotics but still show no signs of improvement could 
be candidates for a broad-range PCR assay to identify if the corneal pathogen is of bacterial 
origin.  By working to improve the sensitivity of PCR testing, clinical laboratories will have 
another diagnostic tool to use in diagnosing patients with keratitis.   
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APPENDIX: TABLES 
Table 1. PCR Primer and Probe Sequences. 
Pathogen Target Size (bp) Primers and Probe 
Pseudomonas 
aeruginosa 
ecfX gene 63 Forward Primer ecfX-F: 5’-CCC ATG CCT ATC ACC CCT T-3’ 
Reverse Primer ecfX-R: 5’-CAA CTG CCC AGG TGC TTG C-3’ 
ecfX TM: 5’- /5G FAM/ATG GCG AGT TGC TGC GCT TCC T/3BHQ-1/-3’ 
Pseudomonas 
aeruginosa 
16S rRNA 567 Forward Primer 27F: 5’-AGA GTT TGA TCM TGG CTC AG-3’  
Reverse 16S1RR-B: 5’-CTT TAC GCC CAR TRA WTC CG-3’ 
514-S: 5’- /56-FAM/TNT TAC CGC GGC TGC TGG CAC G/36-TAMSP/-3’  
Pseudomonas 
aeruginosa 
16S rRNA 144 Forward Primer F2: 5’-GCA CTT TAA GTT GGG AGG AA-3’  
Reverse Primer 16S1RR-B: 5’-CTT TAC GCC CAR TRA WTC CG-3’ 
514-S: 5’- /56-FAM/TNT TAC CGC GGC TGC TGG CAC G/36-TAMSP/-3 
Pseudomonas 
aeruginosa 
16S rRNA 144 Forward Primer F2: 5’-GCA CTT TAA GTT GGG AGG AA-3’  
Reverse Primer 16S1RR-B: 5’-CTT TAC GCC CAR TRA WTC CG-3’ 
TaKaRa SYBR® Premix Ex Taq™ 
Pseudomonas 
aeruginosa 
16S rRNA 792 Forward Primer BAK11W: 5’-AGTTTGATC(A/C)TGGCTCAG-3’  
Reverse Primer BAK2: 5’-GGACTAC(C/T/A)AGGGTATCTAAT-3’ 
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Table 2. P. aeruginosa ecfX and bacterial 16S rRNA Plasmid Dilution Assay Ct values. 
ecfX Dilution Value Ct Value 16S r RNA Dilution Value Ct Value 
10-3 18.51 10-4 18.89 
10-3 18.35 10-4 18.63 
10-4 21.57 10-5 22.25 
10-4 21.72 10-5 22.15 
10-5 25.14 10-6 25.32 
10-5 25.10 10-6 25.15 
10-6 28.93 10-7 28.70 
10-6 28.25 10-7 28.35 
10-7 32.04 10-8 31.96 
10-7 32.07 10-8 32.13 
10-8 35.51 10-9 35.55 
10-8 35.32 10-9 35.69 
10-9 0   
10-9 38.67   
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Table 3. SYBR G reen M elting T emperatures o f S elected B acterial S pecimens from u sing th e F 2 
primer set. 
 
Sample Melting Temperature (°C) 
P. aeruginosa ATCC 
27853 
84.91 
P. aeruginosa K1582 84.66 
P. aeruginosa K1582 84.81 
P. aeruginosa K1581 84.61 
P. aeruginosa K1581 84.77 
P. aeruginosa K1668 84.72 
P. aeruginosa K1668 84.64 
Escherichia coli 84.79 
Escherichia coli 84.97 
Serratia marcescens 85.18 
Serratia marcescens 84.74 
Moraxella lacunata 85.39 
Moraxella lacunata 85.45 
Staphylococcus aureus 85.01 
Staphylococcus aureus 84.75 
 
 
Table 4. Descriptive statistics from de-identified patient sample study. 
Statistic Direct P. aeruginosa 
PCR assay 
16S rRNA gene 
F2 PCR assay 
True-positives 20 20 
True-negatives 20 20 
Sensitivity 75% (15/20) 70% (14/20) 
Specificity 95% (19/20) 100% (20/20) 
Positive Predictive Value 94% (15/16) 100% (14/14) 
Negative Predictive Value 79% (19/24) 77% (20/26) 
Efficiency 85% (34/40) 85% (34/40) 
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Table 5. De-identified patient study sample IDs with real-time PCR results from both assays. 
De-identified Patient 
Sample ID# 
Expected results:  
True positive (P) or 
true negative (N) 
Actual results: 
ecfX PCR assay 
Actual results: 
F2 16S rRNA PCR assay 
9893 P P P 
1410 N N N 
9516 P P N 
8753 N N N 
1829 N N N 
9742 P P P 
T39 P P P 
T44 P P P 
T501 N N N 
586 N N N 
T157 P P P 
1229 N N N 
T192 P N N 
9956 P P P 
T454 N N N 
T238 P N N 
T545 N N N 
611 N N N 
T675 N N N 
8834 P P P 
T525 N N N 
9402 P P P 
1118 N N N 
9748 P P P 
9471 P N N 
1333 N N N 
T902 N N N 
9495 P P N 
9821 N P N 
9551 P P P 
T625 N N N 
9398 P P P 
9856 P N N 
575 N N N 
9691 P P P 
321 N N N 
9328 P N P 
T607 N N N 
602 N N N 
T273 P P P 
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Table 6. T otal D NA c oncentration val ues (calculated u sing t he N anoDrop 2000)  of pur ified de -
identified patient samples, which were detected by the ecfX and F2 16S rRNA real-time PCR assays. 
 
De-identified Patient 
Sample ID# 
DNA Concentration (ng/µl) 
ecfX PCR purified product 
DNA Concentration (ng/µl) 
F2 16S rRNA purified product 
9893 15.5 6.5 
9516 13.2 - 
9742 11.2 11.5 
T39 11.7 9.2 
T44 11.3 5.6 
T157 14.5 9.1 
9956 14.7 11.3 
8834 16.0 7.9 
9402 14.7 9.9 
9748 8.7 5.9 
9495 10.7 - 
9551 12.1 5.1 
9398 14.6 6.4 
9691 10.2 6.9 
9328 - 7.0 
T273 10.9 10.5 
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